Zacks Investment Research lowered shares of Senestech, Inc. (NASDAQ:SNES) from a hold rating to a sell rating in a report issued on Friday morning.

According to Zacks, “SenesTech, Inc. developed technology for managing animal pest populations through fertility control as opposed to a lethal approach. The Company’s fertility control product candidate, ContraPest(R), will be marketed for use initially in controlling rat infestations. SenesTech, Inc. is based in Flagstaff, Arizona. “

Shares of Senestech (NASDAQ SNES) traded down 12.86% during trading on Friday, hitting $1.83. 118,608 shares of the stock were exchanged. The firm has a 50 day moving average of $2.05 and a 200-day moving average of $4.83. The stock’s market cap is $18.89 million. Senestech has a 52-week low of $1.83 and a 52-week high of $10.69.

Senestech (NASDAQ:SNES) last released its earnings results on Thursday, August 10th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.07). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.10 million. Equities research analysts anticipate that Senestech will post ($1.30) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Senestech, Inc. (SNES) Downgraded to “Sell” at Zacks Investment Research” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/16/senestech-inc-snes-downgraded-to-sell-at-zacks-investment-research.html.

In related news, Director Grover T. Wickersham bought 15,000 shares of the stock in a transaction dated Tuesday, July 25th. The shares were purchased at an average price of $2.85 per share, with a total value of $42,750.00. Following the completion of the acquisition, the director now owns 238,600 shares of the company’s stock, valued at $680,010. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Julia Ann Williams bought 10,000 shares of the stock in a transaction dated Wednesday, July 26th. The stock was bought at an average cost of $3.21 per share, for a total transaction of $32,100.00. Following the acquisition, the director now directly owns 11,950 shares of the company’s stock, valued at approximately $38,359.50. The disclosure for this purchase can be found here. In the last three months, insiders bought 54,100 shares of company stock worth $155,730 and sold 13,411 shares worth $35,333. 27.40% of the stock is currently owned by insiders.

An institutional investor recently bought a new position in Senestech stock. White Pine Capital LLC bought a new position in Senestech, Inc. (NASDAQ:SNES) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 19,250 shares of the company’s stock, valued at approximately $110,000. White Pine Capital LLC owned approximately 0.19% of Senestech as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 15.34% of the company’s stock.

Senestech Company Profile

SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.

Receive News & Stock Ratings for Senestech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senestech Inc. and related stocks with our FREE daily email newsletter.